Spotlight On... Philips preps for billion-dollar deals in wake of Lighting IPO; Stentys' stent for long coronary lesions gets CE mark; FDA clears Astute Medical's improved NephroCheck Test; and more...

Royal Philips ($PHG) has started making noises as if all that cash from its recent IPO for its Lighting business is already burning a hole in its pocket. The company's CEO Frans van Houten told Bloomberg that Philips is looking to make more acquisitions along the lines of its $1.2 billion buy of catheter-based visualization and treatment player Volcano, as well as smaller deals. More

> Stentys nabbed a CE mark for the longest version of its Xposition stent for coronary lesions. Release

> The FDA cleared some improvements to Astute Medical's NephroCheck Test Kit that will extend the product's shelf life. Release

> NeuroMetrix ($NURO) closed a $21.3 million private placement of preferred stock and warrants and used $13.8 million to redeem outstanding preferred stock. Release

Suggested Articles

Abbott launched a rapid coronavirus test able to deliver positive results in as little as five minutes, from a table-top box the size of a toaster.

The FDA will be working with government and public-private partners to distribute and evaluate 3D designs and models.

The FDA issued a wide-ranging emergency policy allowing alternative devices to be used as potentially lifesaving ventilators amid new shortages.